federal_register: 2021-16046
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
This data as json
| document_number | title | type | abstract | publication_date | pub_year | pub_month | html_url | pdf_url | agency_names | agency_ids | excerpts |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021-16046 | Product-Specific Guidance for Olodaterol Hydrochloride; Tiotropium Bromide; Draft Guidance for Industry; Availability | Notice | The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Draft Guidance for Olodaterol Hydrochloride; Tiotropium Bromide." The draft guidance, when finalized, will provide product-specific recommendations on, among other things, the information and data needed to demonstrate bioequivalence (BE) to support abbreviated new drug applications (ANDAs) for olodaterol hydrochloride; tiotropium bromide inhalation spray. | 2021-07-28 | 2021 | 7 | https://www.federalregister.gov/documents/2021/07/28/2021-16046/product-specific-guidance-for-olodaterol-hydrochloride-tiotropium-bromide-draft-guidance-for | https://www.govinfo.gov/content/pkg/FR-2021-07-28/pdf/2021-16046.pdf | Health and Human Services Department; Food and Drug Administration | 221,199 | The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Draft Guidance for Olodaterol Hydrochloride; Tiotropium Bromide." The draft guidance, when finalized, will provide... |